SARS-CoV-2 infection perturbs enhancer mediated transcriptional regulation of key pathways.


Journal

PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922

Informations de publication

Date de publication:
08 2023
Historique:
received: 06 02 2023
accepted: 28 07 2023
revised: 22 08 2023
medline: 24 8 2023
pubmed: 10 8 2023
entrez: 10 8 2023
Statut: epublish

Résumé

Despite extensive studies on the effects of SARS-CoV-2 infection, there is still a lack of understanding of the downstream epigenetic and regulatory alterations in infected cells. In this study, we investigated changes in enhancer acetylation in epithelial lung cells infected with SARS-CoV-2 and their influence on transcriptional regulation and pathway activity. To achieve this, we integrated and reanalyzed data of enhancer acetylation, ex-vivo infection and single cell RNA-seq data from human patients. Our findings revealed coordinated changes in enhancers and transcriptional networks. We found that infected cells lose the WT1 transcription factor and demonstrate disruption of WT1-bound enhancers and of their associated target genes. Downstream targets of WT1 are involved in the regulation of the Wnt signaling and the mitogen-activated protein kinase cascade, which indeed exhibit increased activation levels. These findings may provide a potential explanation for the development of pulmonary fibrosis, a lethal complication of COVID-19. Moreover, we revealed over-acetylated enhancers associated with upregulated genes involved in cell adhesion, which could contribute to cell-cell infection of SARS-CoV-2. Furthermore, we demonstrated that enhancers may play a role in the activation of pro-inflammatory cytokines and contribute to excessive inflammation in the lungs, a typical complication of COVID-19. Overall, our analysis provided novel insights into the cell-autonomous dysregulation of enhancer regulation caused by SARS-CoV-2 infection, a step on the path to a deeper molecular understanding of the disease.

Identifiants

pubmed: 37561814
doi: 10.1371/journal.pcbi.1011397
pii: PCOMPBIOL-D-23-00175
pmc: PMC10443870
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1011397

Informations de copyright

Copyright: © 2023 Yedidya et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Clin Epigenetics. 2020 Oct 21;12(1):156
pubmed: 33087172
Nucleic Acids Res. 2015 Jul 1;43(W1):W39-49
pubmed: 25953851
J Virol. 2021 Jun 24;95(14):e0013021
pubmed: 33893170
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Biochem J. 2014 Jul 1;461(1):15-32
pubmed: 24927120
Arch Virol. 2021 Mar;166(3):675-696
pubmed: 33462671
Sci Rep. 2019 Jun 27;9(1):9354
pubmed: 31249361
J Mol Cell Cardiol. 2020 Jul;144:63-65
pubmed: 32422320
Front Immunol. 2021 Apr 13;12:666693
pubmed: 33927728
J Med Virol. 2021 Mar;93(3):1378-1386
pubmed: 33107641
Int J Mol Sci. 2022 May 09;23(9):
pubmed: 35563673
Bioinformatics. 2011 Apr 1;27(7):1017-8
pubmed: 21330290
Cell Death Differ. 2021 Jun;28(6):2019-2021
pubmed: 33981020
Mol Cell Biol. 2013 Aug;33(15):2810-6
pubmed: 23716588
Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11154-9
pubmed: 19549856
Curr Opin Virol. 2013 Jun;3(3):251-9
pubmed: 23601957
Genome Biol. 2014;15(12):550
pubmed: 25516281
Front Pharmacol. 2021 Apr 20;12:631879
pubmed: 33995033
Cell. 2021 May 13;184(10):2618-2632.e17
pubmed: 33836156
Nat Microbiol. 2023 Apr;8(4):679-694
pubmed: 36959507
Nucleic Acids Res. 2018 Jan 4;46(D1):D794-D801
pubmed: 29126249
Nature. 2021 Jul;595(7865):114-119
pubmed: 33915568
Eur Respir J. 2020 Nov 26;56(5):
pubmed: 32859680
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Front Immunol. 2021 Nov 10;12:750969
pubmed: 34858407
Genome Biol. 2003;4(4):R28
pubmed: 12702209
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Genome Med. 2022 Nov 29;14(1):134
pubmed: 36443794
Curr Opin Virol. 2017 Oct;26:74-80
pubmed: 28780440
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
J Biol Chem. 2003 Oct 17;278(42):41420-30
pubmed: 12882970

Auteurs

Yahel Yedidya (Y)

The Lautenberg Center for Immunology and Cancer Research, IMRIC, Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Daniel Davis (D)

The Lautenberg Center for Immunology and Cancer Research, IMRIC, Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Yotam Drier (Y)

The Lautenberg Center for Immunology and Cancer Research, IMRIC, Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH